ReviewCells2022
Current Understanding of Asthma Pathogenesis and Biomarkers.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 6 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- Prebiotics and Synbiotics in Asthma: An Integrative Review of Human Trials and Murine Meta-Analysis.Nutrients · 2026Pooled it
- Genetic and environmental risk factors of asthma: a narrative review.Frontiers in immunology · 2026Pooled it
- Impact of oral bacterial lysates on asthma control and immune parameters in children: evidence from an updated systematic review and meta-analysis of randomized trials.Frontiers in pharmacology · 2026Pooled it
- Efficacy of non-pharmacological interventions for childhood asthma: a systematic review and network meta-analysis.BMC pediatrics · 2025Pooled it
- Global research trends in obesity-related asthma (2004-2023): a bibliometric analysis.Frontiers in nutrition · 2025Pooled it
- Neutrophil-to-lymphocyte ratio as a biomarker for asthma identification and severity stratification: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Effect of Buteyko breathing technique on clinical and functional parameters in adult patients with asthma: a randomized, controlled study.European journal of medical research · 2024Trial
- Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).Immunotherapy · 2024Trial
- Respiratory mucosal immunity: Biological functions, diseases, prevention and therapy.Genes & diseases · 2026Review
- Roles of alarmins in human small airways are independent of immune cells.Respiratory research · 2026Article
- Population-specific patterns of IgE sensitization in Northwest China.Clinics (Sao Paulo, Brazil) · 2026Article
- Heavy moms, wheezy kids: how maternal obesity harms breathing in offspring.American journal of respiratory cell and molecular biology · 2026Review
- Immune Cell-Mediated Causal Link Between Gut Microbiota Traits and Childhood Asthma: Evidence From Mendelian Randomization and Metagenomic Sequencing.The clinical respiratory journal · 2026Article
- Airway structural involvement detected by quantitative computed tomography in controlled and uncontrolled asthma.BMC pulmonary medicine · 2026Observational
- Astragalus polysaccharide mitigates the airway inflammation in bronchial asthma by regulating Hedgehog/NLRP3/GSDMD pathway.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
- Article
- Dectin-1 epigenetic reprogramming rescues senescent-like Treg function in allergic asthma.Life science alliance · 2026Article
- Global, regional, and national burden of chronic obstructive pulmonary disease and asthma from 1990 to present: risk attributions and projections to 2050.Internal and emergency medicine · 2026Article
- Nanozymes as Emerging Therapeutics for Asthma: A Redox-Responsive and Immunomodulatory Strategy.Biomedicines · 2026Review
- Harnessing breath biomarkers for pneumonia diagnosis and prognosis.Expert review of respiratory medicine · 2026Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Asthma is a heterogeneous lung disease with variable phenotypes (clinical presentations) and distinctive endotypes (mechanisms). Over the last decade, considerable efforts have been made to dissect the cellular and molecular mechanisms of asthma. Aberrant T helper type 2 (Th2) inflammation is the most important pathological process for asthma, which is mediated by Th2 cytokines, such as interleukin (IL)-5, IL-4, and IL-13. Approximately 50% of mild-to-moderate asthma and a large portion of severe asthma is induced by Th2-dependent inflammation. Th2-low asthma can be mediated by non-Th2 cytokines, including IL-17 and tumor necrosis factor-α. There is emerging evidence to demonstrate that inflammation-independent processes also contribute to asthma pathogenesis. Protein kinases, adapter protein, microRNAs, ORMDL3, and gasdermin B are newly identified molecules that drive asthma progression, independent of inflammation. Eosinophils, IgE, fractional exhaled nitric oxide, and periostin are practical biomarkers for Th2-high asthma. Sputum neutrophils are easily used to diagnose Th2-low asthma. Despite progress, more studies are needed to delineate complex endotypes of asthma and to identify new and practical biomarkers for better diagnosis, classification, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.